 | |
- close
- close
|
Business Wire
Nov 13
Comment
Columbia Laboratories, Inc. (Nasdaq: CBRX) today commented that nothing fundamental in the Company’s operations has changed to cause the current market activity in its Common Stock. "Upon recent inquiries from shareholders regarding the significant
Business Wire
Nov 9
Comment
In their American Society of Reproductive Medicine (ASRM) conference wrap-up, Medscape highlighted the article published by them on October 27, 2009, which summarized the results from the largest prospective, randomized clinical study to compare
Business Wire
Nov 5
Comment
Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three- and nine-month periods ended September 30, 2009. Highlights for the quarter and subsequent events included: Total progesterone sales increased 11% and domestic
Business Wire
Oct 28
Comment
Columbia Laboratories, Inc. (Nasdaq: CBRX) has raised approximately $11,772,000 in gross proceeds to the Company through the sale of 10,900,000 shares of its common stock and warrants to purchase 5,450,000 shares of its common stock in a registered
Business Wire
Oct 27
Comment
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. will present at the upcoming Oppenheimer 20th Annual Healthcare Conference. Date: Tuesday,
Business Wire
Oct 23
Comment
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that it has priced a transaction to raise up to approximately $11,772,000 through the sale of up to approximately 10,900,000 shares of its common stock and warrants to purchase 5,450,000
Business Wire
Oct 22
Comment
A prospective, multi-center study demonstrated that in IVF (in vitro fertilization) cycles supplemented with once-daily dosing of Crinone® vaginal progesterone gel and Estrace® oral estrogen, vaginal bleeding is rare in patients who become
Business Wire
Oct 22
Comment
Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on November 5, 2009 to discuss financial results of the third quarter ended September 30, 2009. Robert S. Mills, president and chief executive officer, and Lawrence Gyenes, senior
Business Wire
Oct 21
Comment
Researchers from Brigham & Women’s Hospital in Boston presented data from the largest, prospective, randomized clinical study to date comparing any vaginal progesterone to intramuscular injections of progesterone (IM progesterone) for infertility
Business Wire
Oct 20
Comment
A retrospective analysis, conducted at a large infertility clinic between January 2003 and December 2008, demonstrated that there were no significant differences in pregnancy outcomes with three different progesterone formulations for women aged 35
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
CBRX AT A GLANCE
References
| ||||||
|
|
